FY2025 Earnings Forecast for DGX Issued By Leerink Partnrs

Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Quest Diagnostics in a report issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $9.73 per share for the year, up from their previous estimate of $9.72. The consensus estimate for Quest Diagnostics' current full-year earnings is $9.70 per share. Leerink Partnrs also issued estimates for Quest Diagnostics' FY2026 earnings at $10.65 EPS, FY2027 earnings at $11.59 EPS and FY2028 earnings at $12.69 EPS.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, topping analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. The company had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion.

A number of other equities analysts also recently issued reports on DGX. Wall Street Zen downgraded shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a "neutral" rating in a research note on Tuesday, May 6th. Robert W. Baird raised their target price on shares of Quest Diagnostics from $191.00 to $194.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Truist Financial raised their target price on shares of Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday, April 23rd. Finally, Mizuho raised their target price on shares of Quest Diagnostics from $178.00 to $189.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $185.73.

Quest Diagnostics Stock Down 2.0%

Shares of NYSE DGX traded down $3.45 during midday trading on Wednesday, reaching $168.00. 1,335,607 shares of the company's stock traded hands, compared to its average volume of 994,677. The company has a quick ratio of 1.31, a current ratio of 1.44 and a debt-to-equity ratio of 0.84. The stock's 50 day simple moving average is $176.08 and its 200-day simple moving average is $168.33. Quest Diagnostics has a one year low of $137.71 and a one year high of $182.38. The company has a market cap of $18.76 billion, a price-to-earnings ratio of 21.24, a P/E/G ratio of 2.42 and a beta of 0.49.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Investors of record on Monday, July 7th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date of this dividend is Monday, July 7th. Quest Diagnostics's dividend payout ratio is currently 40.46%.

Insiders Place Their Bets

In related news, SVP Mark E. Delaney sold 874 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the completion of the sale, the senior vice president owned 8,372 shares in the company, valued at $1,471,127.84. This represents a 9.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Quest Diagnostics

Large investors have recently bought and sold shares of the company. Pinnacle Bancorp Inc. boosted its stake in shares of Quest Diagnostics by 126.9% during the 2nd quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company's stock worth $27,000 after purchasing an additional 85 shares during the last quarter. Bruce G. Allen Investments LLC raised its stake in shares of Quest Diagnostics by 57.8% during the first quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company's stock valued at $31,000 after purchasing an additional 67 shares during the period. First Horizon Advisors Inc. increased its stake in shares of Quest Diagnostics by 76.6% in the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company's stock worth $32,000 after buying an additional 82 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in Quest Diagnostics by 157.3% in the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock worth $33,000 after purchasing an additional 118 shares during the period. Finally, NBC Securities Inc. acquired a new position in Quest Diagnostics in the first quarter worth $35,000. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.